QPPV.COM KNOWLEDGE ASSESSMENT

Narsoplimab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Narsoplimab: Classification, Mechanism and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A colleague describes narsoplimab as a general complement inhibitor that blocks all complement activation routes. What is the most accurate correction?

It inhibits MASP-2 in the lectin pathway; this does not establish blockade of other complement pathways It inhibits C5, so it blocks the shared terminal step of all complement pathways It suppresses complement by reducing antibody production It blocks complement only when a patient has infection

Question 2 of 10 Which additional information would be most useful when assessing a suspected infection during narsoplimab treatment?

Organism and site, culture or other diagnostic evidence, immune status, prophylaxis, antimicrobial treatment and outcome Only the date the reporter first contacted the company Only the patient’s body weight and the brand name of the medicine Only whether the infection was listed among common adverse reactions

Question 3 of 10 Serious infections were reported in 10 of 28 patients in the clinical study. How should a reviewer use this finding?

Treat it as an observed proportion in a small, seriously ill population, not as an estimate of drug-attributable risk Conclude that narsoplimab caused infection in exactly 36% of treated patients Dismiss the finding because post-transplant patients are already at risk Use it as a comparative risk estimate against an untreated population

Question 4 of 10 Which dosing statement is most appropriate for a professional using the article as a reference?

The U.S. label describes intravenous dosing once weekly with frequency adjustment for inadequate improvement; exact dose and administration instructions should be checked in the current label The article provides a universal fixed dose that applies in every jurisdiction The dose should be increased whenever any single laboratory value changes The mechanism establishes that oral administration is appropriate

Question 5 of 10 A reviewer sees haemorrhage and thrombocytopenia reported during treatment. What is the most appropriate interpretation?

Assess them as clinical events with timing and context, since they may relate to TA-TMA or transplant care as well as potentially being adverse events Attribute both events to narsoplimab because they are listed among observed adverse reactions Exclude both events because they are expected in transplant patients Treat both as proof that MASP-2 inhibition directly anticoagulates the patient

Question 6 of 10 Which combination best reflects the article’s recommended approach to evaluating a possible narsoplimab safety signal in a transplant population?

Link the molecular target and exposure history with transplant setting, disease criteria, concurrent immunosuppression and measurable outcomes Use the event term alone, without considering disease status or timing Attribute events to the medicine whenever they occur after the first dose Rely only on the mechanism of action and disregard patient-level clinical evidence

Question 7 of 10 Which description most accurately identifies narsoplimab’s molecular target and pathway?

A monoclonal antibody that binds MASP-2 and inhibits the lectin pathway of complement A monoclonal antibody that binds C5 and blocks the terminal complement pathway An anticoagulant that directly inhibits thrombin A replacement enzyme that restores deficient complement activity

Question 8 of 10 How should the differing FDA and EMA outcomes described in the article be interpreted?

They are jurisdiction-specific assessments of the submitted evidence and should not be substituted for one another FDA approval automatically establishes an EU marketing authorisation The EMA negative opinion means the FDA authorisation is no longer valid The differing outcomes show that the product’s molecular target changes by jurisdiction

Question 9 of 10 Which statement best distinguishes narsoplimab’s action from direct treatment of thrombosis?

It inhibits a complement-pathway enzyme and is not a direct anticoagulant It dissolves existing thrombi by activating fibrinolysis It prevents platelet activation by directly binding platelet receptors It replaces supportive transplant care by correcting marrow function

Question 10 of 10 Why is it important to record whether an event changed after narsoplimab was held, stopped or restarted?

The event’s course around interruption or re-exposure can contribute to chronology and causality assessment, though it does not alone prove causation Improvement after stopping always proves the medicine caused the event Worsening after restarting always excludes a relationship to treatment Treatment interruption is relevant only for events already confirmed as drug-induced

QPPV.com

Narsoplimab: Classification, Mechanism and Pharmacovigilance — Knowledge Assessment

Cookie Settings